Han, MK; Criner, GJ; Dransfield, MT; Halpin, DMG; Jones, CE; Kilbride, S; Lange, P; ... Martinez, FJ; + view all Han, MK; Criner, GJ; Dransfield, MT; Halpin, DMG; Jones, CE; Kilbride, S; Lange, P; Lettis, S; Lipson, DA; Lomas, DA; Martin, N; Wise, RA; Singh, D; Martinez, FJ; - view fewer (2020) The Effect of ICS Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study: A Randomized, Double-blind Multicenter Trial. American Journal of Respiratory and Critical Care Medicine 10.1164/rccm.201912-2478OC. (In press).

Preview	Text (Article) Lomas_Impact ICS withdrawal_manuscript_CLEAN.pdf - Accepted Version Download (626kB) | Preview
Preview	Text (Online Data Supplement) Lomas_Impact ICS withdrawal_online data supplement_CLEAN.pdf - Accepted Version Download (625kB) | Preview
Preview	Text (Figure 1) GSK [6564] Figure 1_HR.pdf - Accepted Version Download (489kB) | Preview
Preview	Text (Figure 2) GSK [6564] Figure 2_HR.pdf - Accepted Version Download (302kB) | Preview
Preview	Text (Figure 3) GSK [6564] Figure 3_HR.pdf - Accepted Version Download (291kB) | Preview
Preview	Text (Figure 4) GSK [6564] Figure 4_HR.pdf - Accepted Version Download (280kB) | Preview
Preview	Text (Supplementary Figure 1) GSK [6564] Supp Figure 1_HR.pdf - Accepted Version Download (239kB) | Preview
Preview	Text (Supplementary Figure 2) GSK [6564] Supp Figure 2_HR.pdf - Accepted Version Download (308kB) | Preview
Preview	Text (Supplementary Figure 3) GSK [6564] Supp Figure 3_HR.pdf - Accepted Version Download (293kB) | Preview
Preview	Text (Supplementary Figure 4) GSK [6564] Supp Figure 4_HR.pdf - Accepted Version Download (287kB) | Preview

Abstract

RATIONALE: In the IMPACT trial fluticasone furoate/umeclidinium/ vilanterol (FF/UMEC/VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations. OBJECTIVES: Understand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT results given direct transition from prior maintenance medication to study medication at randomization. METHODS: Exacerbations and change from baseline in trough forced expiratory volume in 1 second (FEV1) and St George's Respiratory Questionnaire (SGRQ) were analyzed by prior ICS use. Exacerbations were also analyzed excluding data from the first 30 days. MEASUREMENTS AND MAIN RESULTS: FF/UMEC/VI significantly reduced annual moderate/severe exacerbation rate versus UMEC/VI in prior ICS users (29% reduction; p<0.001), but only a numerical reduction was seen among prior ICS non-users (12% reduction; p=0.115). To minimize impact from ICS withdrawal, in an analysis excluding the first 30 days, FF/UMEC/VI continued to significantly reduce annual on-treatment moderate/severe exacerbation rate (19%; p<0.001) versus UMEC/VI. Benefit of FF/UMEC/VI versus UMEC/VI was seen for severe exacerbation rates, regardless of prior ICS use (prior ICS users: 35% reduction, p<0.001; non-ICS users: 35% reduction, p=0.018) and overall when excluding the first 30 days (29%, p<0.001). Improvements from baseline with FF/UMEC/VI versus UMEC/VI were also maintained throughout the study for both trough FEV1 and SGRQ regardless of prior ICS use. CONCLUSIONS: These data support important treatment effects from FF/UMEC/VI combination therapy on exacerbation reduction, lung function and quality of life that do not appear to be related to abrupt ICS withdrawal. FUNDING: GSK (CTT116855/NCT02164513). Clinical trial registration available at www.clinicaltrials.gov, ID: NCT02164513. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item